Ventricular remodelling following myocardial infarction progressively leads to loss of contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the calcineurin splicing variant, CnAb1, has beneficial effects on the infarcted heart. However, whether this variant limits necrosis or improves remodelling is still unknown, precluding translation to the clinical arena. Here, we explored the effects and therapeutic potential of CnAb1 overexpression post-infarction.
Introduction
Myocardial infarction (MI) remains a major cause of mortality and hospitalization worldwide. Reperfusion of the blocked artery through percutaneous coronary intervention or thrombolytic therapy reduces infarct size and increases survival. 1 However, even if reperfusion therapies have allowed a dramatic reduction in immediate mortality, infarction survivors are at high risk of suffering from heart failure, arrhythmia, and sudden death. Shortly after reperfusion, millions of cardiomyocytes die due to oxidative stress and are substituted by scar tissue. The mechanical stress experienced by the ventricle progressively causes scar thinning and expansion, leading to dilatation of the left ventricle (LV) and other structural changes collectively known as remodelling. 2, 3 The surviving cardiomyocytes undergo hypertrophy to compensate the loss of contractile capacity, but these changes progressively lead to a decline in cardiac function and eventually to the development of heart failure. Far from being a passive tissue, post-infarction scar tissue is populated by different cell types that contribute to maintaining its integrity, regulate extracellular matrix (ECM) turnover, and prevent dilatation. 2 -4 A few days after infarction a granulation tissue is formed, integrated by leucocytes, new blood vessels, fibroblasts, and myofibroblasts that secrete different ECM components, mainly collagen. 5 Inflammatory cells progressively disappear from the area and the scar matures into an ECM-rich fibrotic tissue. 6 The persistence of myofibroblasts in the infarct region contributes to tissue stability. Progressive loss of these cells causes thinning of the infarcted area and left ventricular dilatation. Whereas a strong ECM in the scar region prevents structural remodelling, collagen accumulation in the remote myocardium has the opposite effect. Interstitial fibrosis increases passive stiffness, causes electrical remodelling, and enhances arrhythmogenicity, further contributing to cardiac remodelling and dysfunction. 2 Therefore, ideal therapies will aim at promoting scar maturation while reducing interstitial fibrosis in the remote myocardium. The molecular mechanisms involved in post-infarction remodelling are not entirely understood. 7 Calcineurin generally plays a detrimental role in the heart, and both protective and deleterious effects have been described for this protein in response to ischaemia/reperfusion. 8 -10 It is both sufficient and necessary to induce maladaptive cardiac hypertrophy, 11, 12 and activation of the transcription factor NFAT (nuclear factor of activated T cells) by calcineurin promotes myocardial remodelling and chamber dilatation following infarction. 13 We recently described that, in contrast to other calcineurin A isoforms, the naturally occurring splicing variant, CnAb1, has a beneficial effect on the heart. CnAb1 has a unique C-terminal domain, not present in any other known protein, that confers its distinct properties. 14 In a chronic MI model with permanent occlusion of the left coronary artery, cardiac-specific overexpression of CnAb1 has a protective effect, improving cardiac function and reducing long-term scar size. 15 The purpose of the present work was to investigate the potential benefit of CnAb1 overexpression in response to ischaemia/reperfusion injury, to determine whether CnAb1 is cardioprotective or whether its beneficial action results from post-infarction effects (i.e. improving postinfarction remodelling), and to explore the potential of CnAb1 for genebased therapies.
Methods

Transgenic mice
Reverse Tet transactivator (rtTA)-CnAb1 mice express the rtTA in a cardiomyocyte-specific manner, 16 which, in turn, induces CnAb1 overexpression from a second transgene in a doxycycline (Dox)-inducible fashion ( Figure 1 ). rtTA mice also express the rtTA in a cardiomyocytespecific manner, but lack the CnAb1 transgene and therefore do not overexpress CnAb1. The rtTA-CnAb1 mouse line was generated by crossing the original TetO-CnAb1 transgenic line, carrying the Tet operator and the CnAb1 cDNA ( Figure 1 ) with the rtTA mouse line. Both rtTA-CnAb1 and rtTA mice were generated in a CBA/Black10 genetic background 16 and inbred in this background for at least eight generations.
Male littermates between 3 and 5 months of age were used for experiments. Dox was administered to mice with diet (0.3%) starting either 3 weeks before infarction or 1 week after infarction, and maintained until mice were sacrificed.
Surgeries and echocardiographic analysis
Myocardial infarction was induced in rtTA-CnAb1 (n ¼ 28) and rtTA mice (n ¼ 21) by ligation of the left coronary artery for 30 min followed by reperfusion of the artery. Surgeries were performed under mechanical ventilation with 3-3.5% sevoflurane. Mice received analgesic treatment with buprenorphine (0.3 mg/kg, s.c.) after surgery. The mortality rate in the first 24 h post-infarction was 38%; no mortality was found afterwards. Cardiac function, chamber dilatation, and wall thickness were analysed by transthoracic echocardiography 3 and 28 days after infarction, as well as in uninfarcted mice, using a Vevo 2100 system and a 45-MHz probe (Visualsonics, Toronto, Canada). Measurements were taken by a blinded operator with mice placed on a heating pad under light anaesthesia with sevoflurane adjusted to obtain a target heart rate of 500 + 50 bpm. 15 Two-dimensional (2D) and M-mode echocardiography images were recorded in a long and short view at the level of the papillary muscles. LV end-systolic and enddiastolic volumes as well as LV ejection fraction were measured from 2D parasternal long axis using the area -length method. Animals were sacrificed by gradually filling the chamber with carbon dioxide. For the analysis of infarct size using echocardiography, regional left ventricular function was evaluated in the parasternal long-axis view. The LV wall was subdivided into six segments (basal, mid, and apical in the anterior and posterior walls). Each segment was scored by an independent blinded evaluator based on its motion and systolic thickening, according to the guidelines of the American Society of Echocardiography 17 (1, normal or hyperkinetic; 2, hypokinetic; 3, akinetic, negligible thickening; 4, dyskinetic, paradoxical systolic motion; and 5, aneurysmal, diastolic deformation). The number of dysfunctional segments was quantified, and the total score representing the sum of the score of the six individual segments in each heart was calculated. All experiments were approved by the local Ethics Committee at the Centro Nacional de Investigaciones Cardiovasculares. The investigation conforms to the principles of Laboratory Animal Care, which are formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health Publication 85-23, 1996).
Western blot
Western blot was carried out using the following primary antibodies as previously described: 18 anti-phospho-Akt-Ser473, anti-Akt, anti-phosphomTOR-Ser 2448, anti-mammalian target of rapamycin (mTOR) (Cell Signaling), anti-hypoxia-inducible factor 1a (HIF1a) and anti-Periostin (Novus Biochemicals), anti-vascular endothelial growth factor (VEGF), anti-Lox and anti-CD31 (Abcam), and anti-fibronectin (Sigma). Anti-CnAb1 has been previously described. 14 Brightness and contrast were linearly adjusted using Photoshop CS5.
Histology and immunohistochemistry
Samples were fixed in paraformaldehyde (4% in PBS) for 48 h, washed in PBS, dehydrated, and included in paraffin. Five-micron thick sections were stained following Masson's trichrome protocol. 14 Images were quantified using ImageJ (NIH, USA). Scar length was determined in Masson's trichromestained sections using the midline method, which best correlates with functional measurements. 19 In this method, the infarct length is measured as the length of the midline of the infarcted wall, in which .50% of the wall thickness is composed of scar tissue. 19 Scar length represents the percentage of infarct length with respect to the length of the whole LV circumference. Medium/large blood vessels in the infarct region were visually scored in Masson trichrome-stained sections. These vessels would be .20 mm in diameter and typically surrounded by a smooth muscle layer that makes them easily identifiable. In parallel, vessels were stained by immunohistochemistry using anti-a-smooth muscle actin (SMA). In both experiments, the number of vessels was determined in the infarct region only and divided by the infarct area. Vessels were quantified in three non-consecutive sections for each mouse. Capillaries were stained using biotin-conjugated Isolectin B4 (Sigma) and scored in two separate 40× microscope fields. Apoptosis in cardiomyocytes (in the whole section) and fibroblasts (in the infarct region) was analysed using Tunel and immunostaining with antitroponin I (cardiomyocytes) or anti-periostin (fibroblasts).
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RNA isolation and quantitative reverse-transcribed polymerase chain reaction
After sacrificing the animals, mice were perfused with PBS, hearts were excised, and samples from the infarct region, border zone, and remote myocardium were separated and snap-frozen in liquid nitrogen. Total RNA was isolated using the RNeasy kit from Qiagen, with DNAse digestion on the column. cDNA was synthesized from 100 ng of total RNA using random hexamers and a High Capacity cDNA Reverse Transcription kit (Applied Biosystems) in a 10-mL reaction. Quantitative reverse-transcribed polymerase chain reaction (qRT-PCR) was carried out in an AB9700 thermocycler (Applied Biosystems) using Taqman chemistry or SYBR green (Applied Biosystems).
The following Taqman probes were used: Acta1 (Mm00808218_g1), Nppb/brain natriuretic peptide (BNP) (Mm01255770_g1), Col1a1 (Mm00801666_g1), Lox (Mm00495386_m1) Thy1 (Mm00493681_m1), and Acta2 (Mm01204962_gh). Gene expression was normalized to 18S rRNA levels quantified simultaneously using a VIC-labelled probe (4310893E, Applied Biosystems). CnAb1 and CD31 expression were quantified using SYBR green and the following primers and conditions: CnAb1 forward:
′ , CD31 forward: AATGGCAACTGGAGC-GAGCACT, CD31 reverse: GGAGAAGGCGAGGAGGGTTAGGT; 2 min at 508C, 10 min at 958C, and 40 cycles of 15 s at 958C, 30 s at 608. CnAb2 primers were previously described. 15 qRT-PCR data were analysed using the LinReg software in order to estimate the efficiency rates and the C t values. 20 
Angiotubes
Neonatal cardiomyocytes were isolated from rtTA-CnAb1 and rtTA mice as described previously. 21 Neonatal mice were sacrificed by cervical dislocation. A total of 750 000 cells/well were seeded in 12-well plates and grown in the presence of 10% foetal calf serum for 2 days. Cells were then washed and cultured in serum-free medium for 2 days in the presence of 2 mg/mL of Dox, 0.1 mM rapamycin, or DMSO (1 : 1000) as indicated in the figures. Conditioned medium was cleared by centrifugation and used for angiotube assays as follows. Matrigel (Becton Dickinson) diluted 1 : 3 in DMEM was added to 96-well plates (100 mL/well) and allowed to polymerize for 60 min. Human umbilical cord vascular endothelial cells (HUVECs; Promocell) 22 were seeded at a density of 30 000 cells/well in the presence of the different conditioned mediums and allowed to form tubes for 6 h. Where indicated, neutralizing anti-VEGF antibody (R&D Systems) was added to the culture (2 ng/mL). Anti-troponin I (Abcam) was used as a negative control antibody. Pictures were taken with a Nikon eclipse TI microscope, and the number of tube network nodes was quantified for each well. Experiments were performed in triplicate and all experiments were repeated at least three times.
Statistics
Data are presented as mean + SE. In echocardiographic data, the same mice were analysed 3 and 28 days post-infarction, with non-infarcted animals representing a different group of mice. To test for statistical significance, data were analysed by two-way ANOVA followed by Bonferroni post-test for multiple comparisons. In addition, a two-way ANOVA with repeated measures followed by Bonferroni post-test was applied to compare mice at 3 vs. 28 days post-infarction. Group differences in qRT-PCR and histological quantifications were analysed by one-way ANOVA followed by Dunnett's post-test to compare Dox-untreated mice. Angiotubes were analysed by Student's t-test or two-way ANOVA, followed by Bonferroni's post-test depending on the number of variables. Data were analysed with GraphPad 
Results
Cnab1 improves cardiac function and remodelling after ischaemia/reperfusion
To determine the potential benefit of CnAb1 overexpression in the context of MI with reperfusion, we developed double transgenic mice in which CnAb1 expression is induced three-to four-fold specifically in cardiomyocytes upon administration of Dox in the diet (rtTA-CnAb1 mice, Figure 1) . As negative controls, to test the effect of Dox itself, we used mice that overexpress the same rtTA transactivator but lack the CnAb1 transgene (rtTA mice). As a first approach, we administered Dox starting 3 weeks before surgery and maintained it throughout the experiment. We induced MI by occluding the left coronary artery for 30 min followed by reperfusion, and analysed the mice 3 and 28 days later by echocardiography. rtTA-CnAb1 and rtTA mice showed functional decline and chamber dilatation 3 days post-infarction regardless of Dox treatment (Figure 2A Figure 2A , grey bars), while animals not receiving Dox showed no improvement (No Dox; Figure 2A , white bars). Improved function was accompanied by reduced ventricular dilation in Dox-treated rtTA-CnAb1 mice ( Figure 2C and Table 1 ). In contrast, Dox administered to rtTA mice had no effect on cardiac function or chamber dilation ( Figure 2B and  D) . Of note, neither CnAb1 nor CnAb2 (the CnAb-splicing isoform that carries the full CnA autoinhibitory domain) mRNA expression showed much variation in response to MI itself ( Figure 1G ).
Cnab1 induces recovery rather than protection
The results obtained at 3 days post-infarction suggested that CnAb1 offered no protection against reperfusion injury, whereas the improvement observed at 28 days suggested a positive effect post-infarction. To further discriminate between the protective and recovery effects of CnAb1 overexpression, we treated rtTA-CnAb1 mice with Dox starting 1 week post-infarction, once the scar has developed (Dox post-MI, black bars). Interestingly, a significant enhancement of cardiac function was observed in these mice (Figure 2A) , which was accompanied by reduced ventricular dilatation ( Figure 2C) . Importantly, in all the study, Ligation of the left coronary artery (30 ′ ischaemia followed by reperfusion) was performed in rtTA and rtTA-CnAb1 male transgenic mice, and echocardiography analysis was carried out 3 and 28 days later. Mean values + SE are shown. EF, ejection fraction; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVPWd, left ventricular posterior wall in diastole; IVSd, interventricular septum in diastole; HW/BW, heart weight/body weight ratio; n, number of mice analysed. CnAb1 promotes infarct vascularization the same mice were sequentially analysed at 3 and 28 days. The functional decline observed at 3 days post-infarction and the subsequent improvement observed at 28 days in Dox-treated rtTA-CnAb1 mice (see Supplementary material online, Figure S1 and Table 1 ) demonstrate that CnAb1 induces functional recovery, rather than protection from infarction.
Cnab1 prevents infarct expansion and improves remote myocardium remodelling
We next analysed the impact that CnAb1 overexpression has on infarct expansion. We found that overexpression of CnAb1 before infarction resulted in reduced scar length 28 days post-infarction, compared with mice untreated with Dox ( Figure 3A and Supplementary material online, Figure S2 ). Importantly, a similar effect was achieved when CnAb1 was induced after infarction. In Dox-treated rtTA-CnAb1 mice, scar length at 28 days post-infarction (20.47 + 3.85% in mice treated pre-MI and 14.23 + 4.16% in mice treated post-MI) remained similar to that observed at 7 days in untreated mice (21.52 + 2.90%). Echocardiographic analysis showed that CnAb1 overexpression results in a reduction in the number of LV segments with dysfunctional motility 28 days after infarction (see Supplementary material online, Table S1 ). This was particularly evident in the mid-anterior segment, confirming the reduced infarct size observed by histological methods. In addition, CnAb1-overexpressing mice showed thicker scars than control mice ( Figure 3B ), suggesting that CnAb1 prevents infarct expansion. Induction of CnAb1 also resulted in higher expression of collagen Ia1 in the scar region, together with increased expression of lysyl oxidase, which crosslinks collagen and elastin molecules into mature fibres, the fibroblast proliferation marker Thy1/CD90, and a-smooth muscle actin ( Figure 3C-F) . We also detected increased expression of periostin, fibronectin, and lysyl oxidase proteins in the infarct region of CnAb1-overexpressing mice ( Figure 3G) . rtTA mice showed no changes in scar length, thickness, or expression of fibrosis markers upon Dox administration ( Figure 3A -G and Supplementary material online, Table S1 ). To investigate whether reduced infarct expansion was accompanied by improved fibroblast survival, we quantified the percentage of apoptotic fibroblasts by Tunel staining. As shown in Supplementary material online, Figure S3A , only a very low degree of fibroblast apoptosis was detected in the infarct region 28 days post-infarction, and no significant difference was observed among the groups.
To determine whether changes in infarct expansion were paralleled by improved remodelling of the remote myocardium, we analysed the cardiomyocyte area and the expression of heart failure markers in this region. CnAb1 overexpression either before or after infarction significantly reduced the cross-sectional area of cardiomyocytes and the wall thickness in the remote myocardium ( Figure 4A and Table 1 ). This was accompanied by a significant reduction of a-skeletal actin, BNP, and collagen Ia1 in the remote myocardium of these mice ( Figure 4B-D) . A trend towards reduced cardiomyocyte apoptosis was also detected in CnAb1-overexpressing mice, although the percentage of apoptotic cardiomyocytes 28 days post-infarction was low (see Supplementary material online, Figure S3B ). In contrast, Dox administered to rtTA mice had no effect on cardiomyocyte size or expression, heart failure, or fibrosis markers or apoptosis ( Figure 4A-D  and Supplementary material online, Figure S3B ).
Improved vascularization in the infarct region of CnAb1-overexpressing mice
The effect of CnAb1 on infarcted hearts is reminiscent of cardiomyocyte activation of the HIF1a, which drives the expression of angiogenic factors and promotes infarct vascularization. 23 To determine whether more active, thicker scars were supported by enhanced vascularization in CnAb1-overexpressing mice, we quantified the amount of blood vessels in the scar region. We observed that induction of CnAb1 overexpression either pre-or post-infarction increased the number of blood vessels in the infarcted region ( Figures 5 and 6A and B) . This was confirmed by an up-regulation of CD31 and a-SMA mRNA in the same region ( Figures 3F and G and 6C) . A mild induction in CD31 mRNA expression and in the number of capillaries were also detected in the remote area upon CnAb1 induction ( Figure 6E and F ) .
Cnab1 promotes vascularization by activating the Akt signalling pathway
We have previously shown that CnAb1 activates the Akt pathway through its unique C-terminal domain. 15 Akt is known to induce angiogenesis in the heart by promoting expression of VEGF. 24 We therefore investigated the role of this signalling pathway in the angiogenic response elicited by CnAb1. We observed that Dox stimulation of rtTA-CnAb1 mice induced expression of VEGF and the HIF1a in the remote myocardium ( Figure 7A ). This was accompanied by increased CD31 expression and activation of the Akt/mTOR pathway. No changes were observed in rtTA mice upon Dox treatment.
To test whether the paracrine angiogenic effect of CnAb1 was reproduced in culture, we used the assay for HUVEC angiotube formation on matrigel. 25 As shown in Figure 7B , conditioned medium from Doxtreated rtTA-CnAb1 cardiomyocytes stimulated angiotube formation by HUVEC, whereas that of untreated cells or rtTA cardiomyocytes had no effect. This effect was blocked by a neutralizing anti-VEGF antibody ( Figure 7C ), suggesting that VEGF mediates the paracrine effect of CnAb1-overexpressing cardiomyocytes on endothelial cells. Interestingly, treatment of rtTA-CnAb1 cardiomyocytes with the inhibitor of the Akt/mTOR pathway rapamycin blocked the induction of angiotube formation by the conditioned medium ( Figure 7D ). Rapamycin also prevented the induction of VEGF secretion by Dox-treated rtTA-CnAb1 cardiomyocytes ( Figure 7E ). These results suggest that CnAb1 activates Akt/mTOR in cardiomyocytes to induce VEGF secretion and paracrine activation of angiogenesis.
Discussion
We show here that, in contrast to other calcineurin isoforms, CnAb1 has beneficial effects on the heart after reperfusion injury. CnAb1 reduces ventricular dilatation and improves function even when overexpressed 1 week after infarction. By activating the Akt/mTOR pathway, CnAb1 promotes secretion of angiogenic mediators by cardiomyocytes and enhances vascularization of the infarct region, thus precluding infarct expansion and improving heart remodelling. Our results suggest that the beneficial effects of CnAb1 overexpression involve the prevention of heart remodelling rather than cardioprotection. The significant ventricular dilatation and decline in cardiac function observed here at Day 3 post-infarction in all experimental groups strongly suggest that CnAb1 exerts its beneficial effects by improving myocardial remodelling after infarction, rather than by protecting from reperfusion injury. This is further supported by the fact that induction of CnAb1 as late as 1 week post-infarction improves cardiac function and reduces ventricular dilatation. The scar tissue in CnAb1-overexpressing mice is thicker and richer in collagen, matrix crosslinking enzymes and activated fibroblasts, which result in reduced infarct expansion.
We previously showed that CnAb1 overexpression leads to reduced scar formation after permanent occlusion of the left coronary artery. 15 In the chronic infarction model, scars from CnAb1-overexpressing mice showed reduced fibroblast number and collagen expression. In contrast, Dox-treated rtTA-CnAb1 mice show thicker scars with increased collagen expression after ischaemia reperfusion. This apparent discrepancy is likely due to the different response to permanent ischaemia and to CnAb1 promotes infarct vascularization reperfusion injury. Chronic MI eventually results in the death of most cells in the infarct region, leading to loss of ECM production and infarct expansion. In that context, the reduced infarct size observed in the presence of CnAb1 is likely due to reduced myocardial damage, which is consistent with the improved function already observed 7 days post-infarction. 15 In contrast, reperfusion injury reduces cardiomyocyte death and promotes a stronger angiogenic response in the infarcted myocardium. 26 Our results suggest that CnAb1 promotes VEGF expression from cardiomyocytes to improve vascularization of the infarcted region, while stimulating fibroblast proliferation and ECM production in this area. In addition, although we only detected a very low degree of fibroblast apoptosis 28 days post-infarction, we cannot exclude the possibility that better vascularization improves fibroblast survival at earlier time points. The increase in fibroblasts and myofibroblasts in the scar tissue will contribute to increased ECM turnover and to the maintenance of the scar structure, thus preventing remodelling. Distinct effects on heart remodelling in response to permanent ischaemia and reperfusion injury have been described for other factors like growth differentiation factor15. 27 In addition, the remote myocardium of CnAb1-overexpressing mice shows reduced cardiomyocyte hypertrophy, together with lower expression of collagen and heart failure markers. This reduction in myocardial remodelling is likely the result of the limited infarct expansion. Importantly, all these effects were observed even when CnAb1 overexpression was induced late after infarction, indicating that CnAb1's main target is not only the reduction of cardiomyocyte death or inflammation, but also the prevention of infarct expansion and chamber dilatation.
Molecular therapies capable of improving ventricular function after infarction are scarce. Overexpression of sonic hedgehog starting 5 days post-infarction attenuates remodelling and improves function. 28 Inhibition of Wnt signalling with Frizzled antagonist peptides reduces infarct expansion and prevents ventricular dilatation. 29 This effect was also achieved when the peptide was administered 2 weeks after infarction, suggesting that Wnt signalling has a detrimental effect on heart remodelling rather than on early infarct healing. In both cases, the improvement in cardiac remodelling was accompanied by enhanced infarct vascularization. In this same regard, overexpression of the angiogenesis regulator HIF1a also improves vascularization and function, and reduces infarct size in transgenic mice. 23 However, chronic overexpression of HIF1a has detrimental effects on the heart. 30 Similarly, short-term Akt activation in cardiomyocytes induces VEGF and angiogenesis, but sustained activation induces maladaptive hypertrophy and fibrosis. 24 We show here that CnAb1 induces angiogenesis by promoting VEGF expression in an Akt/mTOR-dependent manner. In contrast to sustained Akt activation, CnAb1 overexpression in cardiomyocytes improves infarct vascularization, cardiac remodelling, and function without inducing the detrimental side effects observed after sustained Akt or HIF1a overexpression. Taken together, our results emphasize the therapeutic potential of CnAb1 and suggest that it may be an excellent candidate for gene therapies aimed at reducing ventricular remodelling and improving cardiac function post-infarction. We demonstrate that these beneficial effects can be achieved by inducing CnAb1 expression late after infarction. Our work constitutes a first step for the translation of these findings to the clinical setting.
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